Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support
the bioenergetic and biosynthetic demands of proliferation. We tested the small-molecule …

Efficacy of EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, to treat human
non-small cell lung cancers (NSCLCs) with activating mutations in EGFR is not persistent …

Genetic mutations in tumor cells cause several unique metabolic phenotypes that are critical
for cancer cell proliferation. Mutations in the tyrosine kinase epidermal growth factor receptor …

Regulated by the tumor microenvironment, the metabolic network of the tumor is
reprogrammed, driven by oncogenes and tumor suppressor genes. The metabolic …

The secondary EGF receptor (EGFR) T790M is the most common mechanism of resistance
to reversible EGFR-tyrosine kinase inhibitors (TKI) in patients with non–small cell lung …

Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have
shown dramatic effects against EGFR mutant lung cancer, patients become resistant by …

Purpose: One of the hallmarks of cancer cells is the excessive conversion of glucose to
lactate under normoxic conditions, also known as the Warburg effect. Here, we tested …

Metabolic reprogramming is critical for cancer cell proliferation. Glutaminolysis which
provides cancer cells with bioenergetics and intermediates for macromolecular synthesis …

Tumor heterogeneity and changes in epidermal growth factor receptor (EGFR) mutation
status over time challenge the design of effective EGFR tyrosine kinase inhibitor (TKI) …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …